Pain News and Research

Latest Pain News and Research

New cutting edge nerve procedure relieves migraine permanently

The Plastic Surgery Center today announced that a 57-year-old Plainfield man reports he is free of constant headache pain after undergoing a new cutting edge nerve procedure to permanently eliminate pain caused by migraines. The procedure was performed by plastic and reconstructive surgeon Dr. Matthew Kaufman, of the Plastic Surgery Center in New Jersey on August 4, 2009.

21 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Vertos Medical raises $15.5 million for U.S. commercialization of the company’s "mild" technology

Medical device company Vertos Medical, Inc., developer of the mild® procedure for lumbar spinal stenosis (LSS), today announced it has completed a $15.5 million Series D financing. New investor, ONSET Ventures, led the round with additional participation from existing Vertos investors CHL Medical Partners, Foundation Medical Partners, Aweida Venture Partners and DFJ Mercury.

20 Oct 2009

Individuals and governments around the globe should join the fight against osteoporosis: IOF

Speaking in Rome, Italy today on the occasion of World Osteoporosis Day, International Osteoporosis Foundation (IOF) CEO Patrice McKenney called for individuals and governments around the globe to join the fight against osteoporosis. "Osteoporosis is a common but devastating disease which we cannot afford to ignore. Immediate measures must be taken to reduce the burden of osteoporotic fractures through prevention, early recognition of fracture risk, and appropriate proven treatment for those in need," she urged.

20 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

RA patients who adhere to their prescription drug regimen have better outcome: Study

Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia.

20 Oct 2009

Fluarix seasonal influenza vaccine approved by the FDA

The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

20 Oct 2009

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.

20 Oct 2009

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

NicOx S.A. announced the presentation of detailed 26-week efficacy, safety and tolerability data from the second pivotal phase 3 study for naproxcinod (the 302 study) yesterday, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

20 Oct 2009

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. for a joint collaboration to develop novel ion channel drugs.

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

Website answers questions about 'end of life'

Questions about end of life are as old as humanity, yet they can be new and overwhelming when someone we care about is dying.

19 Oct 2009

California's community hospitals launch public education and media campaign on H1N1

As preparations for the H1N1 flu season kick into high gear, California's community hospitals have launched a statewide public education and media campaign.

19 Oct 2009

Children with neurological disorders have low skin temperature

Many wheelchair-using children with neurological disorders have much colder hands and feet than other children, and most receive no special help even though they have had these problems for a long time, is revealed in at thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

19 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

Campaign to educate men and women about fibromyalgia

Women and men have opposing views on many topics, and it turns out that they also have different takes on chronic pain.

19 Oct 2009

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Although stem cells sounds innovative and cutting edge, this therapy has been around for quite some time. In today's advanced medical climate stem cells are being used to treat many orthopedic conditions including osteoarthritis of the hip knee and shoulder, partial tears of tendons, muscles, and ligaments including rotator cuff tears, and various back conditions including disc herniations.

19 Oct 2009

Pain News and Research

Latest Pain News and Research

New cutting edge nerve procedure relieves migraine permanently

Positive results from KAI Pharmaceuticals' pain therapeutic program

Vertos Medical raises $15.5 million for U.S. commercialization of the company’s "mild" technology

Individuals and governments around the globe should join the fight against osteoporosis: IOF

Two high blood pressure medicines effective in treating stable ischemic heart disease

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

RA patients who adhere to their prescription drug regimen have better outcome: Study

Fluarix seasonal influenza vaccine approved by the FDA

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

FDA approves new oral medication for renal cell carcinoma

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Website answers questions about 'end of life'

California's community hospitals launch public education and media campaign on H1N1

Children with neurological disorders have low skin temperature

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Campaign to educate men and women about fibromyalgia

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Pain News and Research

Latest Pain News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in